Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   


RGD uses the Human Disease Ontology (DO, for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:visceral leishmaniasis
go back to main search page
Accession:DOID:9146 term browser browse the term
Definition:A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
Synonyms:exact_synonym: KALA-AZAR, SUSCEPTIBILITY TO, 1;   KALA-AZAR, SUSCEPTIBILITY TO, 2;   KALA-AZAR, SUSCEPTIBILITY TO, 3;   KAZA1;   KAZA2;   KAZA3;   Kala Azar;   black fever;   infection by visceral leishmaniasis;   visceral leishmaniasis, susceptibility to, 1;   visceral leishmaniasis, susceptibility to, 3
 primary_id: MESH:D007898
 alt_id: OMIM:608207;   OMIM:611381;   OMIM:611382;   RDO:0005977
 xref: ICD10CM:B55.0;   ICD9CM:085.0;   NCI:C34771;   OMIM:PS608207;   ORDO:507
For additional species annotation, visit the Alliance of Genome Resources.

show annotations for term's descendants           Sort by:
visceral leishmaniasis term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aicda activation-induced cytidine deaminase IMP
mRNA:altered expression:Bcell,CD4Tcell RGD PMID:31001826, PMID:31001826 RGD:32716386, RGD:32716386 NCBI chr 6:122,553,809...122,564,180
Ensembl chr 6:122,553,801...122,564,180
JBrowse link
G Ccl4 chemokine (C-C motif) ligand 4 ISO protein:increased expression:serum RGD PMID:21991751 RGD:5683905 NCBI chr11:83,648,624...83,664,683
Ensembl chr11:83,662,584...83,664,683
JBrowse link
G Ccr2 chemokine (C-C motif) receptor 2 IEP
associated with Malnutrition;mRNA:increased expression:lymph node,spleen: RGD PMID:24818662, PMID:24818662 RGD:8661728, RGD:8661728 NCBI chr 9:124,101,918...124,109,140
Ensembl chr 9:124,101,950...124,113,557
JBrowse link
G Ccr3 chemokine (C-C motif) receptor 3 ISO protein:increased expression:blood, T cell RGD PMID:15379987 RGD:6893393 NCBI chr 9:124,017,825...124,031,692
Ensembl chr 9:124,021,972...124,031,689
JBrowse link
G Ccr5 chemokine (C-C motif) receptor 5 treatment IMP RGD PMID:24617012 RGD:14401738 NCBI chr 9:124,121,543...124,127,183
Ensembl chr 9:124,121,543...124,147,699
JBrowse link
G Cd40 CD40 antigen treatment IMP RGD PMID:14573667 RGD:8547750 NCBI chr 2:165,055,614...165,071,654
Ensembl chr 2:165,055,627...165,072,948
JBrowse link
G Cd40lg CD40 ligand IMP RGD PMID:14573667 RGD:8547750 NCBI chr  X:57,212,143...57,224,042
Ensembl chr  X:57,212,143...57,224,042
JBrowse link
G Crp C-reactive protein, pentraxin-related ISO CTD Direct Evidence: marker/mechanism CTD PMID:10467834 NCBI chr 1:172,698,056...172,699,966
Ensembl chr 1:172,698,055...172,833,031
JBrowse link
G Csf2 colony stimulating factor 2 (granulocyte-macrophage) treatment ISO CTD Direct Evidence: marker/mechanism CTD PMID:17404324, PMID:8035028 RGD:10449527 NCBI chr11:54,247,270...54,249,899
Ensembl chr11:54,247,271...54,249,667
JBrowse link
G Cxcl10 chemokine (C-X-C motif) ligand 10 IEP mRNA:increased expression:liver RGD PMID:16239557 RGD:27095947 NCBI chr 5:92,346,638...92,348,889
Ensembl chr 5:92,346,638...92,348,889
JBrowse link
G Cxcl15 chemokine (C-X-C motif) ligand 15 ISO CTD Direct Evidence: marker/mechanism CTD PMID:22461696 NCBI chr 5:90,794,534...90,803,067
Ensembl chr 5:90,794,534...90,803,067
JBrowse link
G H2-Aa histocompatibility 2, class II antigen A, alpha ISO CTD Direct Evidence: marker/mechanism CTD PMID:23291585 NCBI chr17:34,282,744...34,287,823
Ensembl chr17:34,282,744...34,287,823
JBrowse link
G H2-Eb1 histocompatibility 2, class II antigen E beta ISO CTD Direct Evidence: marker/mechanism CTD PMID:23291585 NCBI chr17:34,305,867...34,316,674
Ensembl chr17:34,305,867...34,316,674
JBrowse link
G Hmox1 heme oxygenase 1 ISO CTD Direct Evidence: marker/mechanism CTD PMID:22461696 NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
JBrowse link
G Ifng interferon gamma treatment IDA
CTD Direct Evidence: therapeutic CTD PMID:1901333, PMID:7854095, PMID:3104456 RGD:8158041 NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
JBrowse link
G Il10 interleukin 10 ISO CTD Direct Evidence: marker/mechanism CTD PMID:15716043, PMID:17404324, PMID:22461696, PMID:29745990 RGD:14975172 NCBI chr 1:131,019,845...131,024,970
Ensembl chr 1:131,019,845...131,024,974
JBrowse link
G Il10ra interleukin 10 receptor, alpha ISO CTD Direct Evidence: therapeutic CTD PMID:15716043 NCBI chr 9:45,253,837...45,269,149
Ensembl chr 9:45,253,837...45,269,149
JBrowse link
G Il18 interleukin 18 susceptibility IMP RGD PMID:16879623 RGD:8655922 NCBI chr 9:50,554,700...50,581,841
Ensembl chr 9:50,554,827...50,581,840
JBrowse link
G Il1b interleukin 1 beta ISO CTD Direct Evidence: marker/mechanism CTD PMID:17404324 NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
JBrowse link
G Il6 interleukin 6 ISO CTD Direct Evidence: marker/mechanism CTD PMID:7554475, PMID:17404324, PMID:22461696 NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
JBrowse link
G Lta lymphotoxin A severity ISO
DNA:polymorphisms RGD PMID:12438370, PMID:15579454 RGD:8548784, RGD:8548789 NCBI chr17:35,203,165...35,205,578
Ensembl chr17:35,203,165...35,205,351
JBrowse link
G Ltb lymphotoxin B IMP RGD PMID:12115620 RGD:8548822 NCBI chr17:35,194,507...35,196,305
Ensembl chr17:35,194,439...35,196,320
JBrowse link
G Mbl2 mannose-binding lectin (protein C) 2 disease_progression
ISO protein:increased expression:serum:
RGD PMID:17357060, PMID:26297290, PMID:26297290, PMID:22995279, PMID:17357060 RGD:8693721, RGD:11522692, RGD:11522692, RGD:8693726, RGD:8693721 NCBI chr19:30,232,906...30,239,687
Ensembl chr19:30,232,942...30,239,687
JBrowse link
G Mir155 microRNA 155 IMP RGD PMID:31182615 RGD:21081525 NCBI chr16:84,714,140...84,714,204
Ensembl chr16:84,714,140...84,714,204
JBrowse link
G Slc11a1 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 ISO CTD Direct Evidence: marker/mechanism CTD PMID:16597321, PMID:17067929 RGD:5684944 NCBI chr 1:74,375,014...74,386,057
Ensembl chr 1:74,375,195...74,386,062
JBrowse link
G Stat4 signal transducer and activator of transcription 4 IMP RGD PMID:24242758 RGD:8661696 NCBI chr 1:51,987,106...52,107,189
Ensembl chr 1:51,987,148...52,107,189
JBrowse link
G Tlr2 toll-like receptor 2 disease_progression IMP RGD PMID:23589575 RGD:15090808 NCBI chr 3:83,836,272...83,841,824
Ensembl chr 3:83,836,272...83,841,767
JBrowse link
G Tnf tumor necrosis factor severity ISO
CTD Direct Evidence: marker/mechanism
CTD PMID:1901333, PMID:22461696, PMID:12438370, PMID:15579454 RGD:8548784, RGD:8548789 NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  disease 13427
    disease of anatomical entity 12903
      endocrine system disease 0
        liver disease 2405
          visceral leishmaniasis 28
Path 2
Term Annotations click to browse term
  disease 13427
    disease of anatomical entity 12903
      nervous system disease 10459
        sensory system disease 5054
          skin disease 2637
            Infectious Skin Diseases 163
              Parasitic Skin Diseases 57
                leishmaniasis 53
                  visceral leishmaniasis 28
paths to the root


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.